Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Sumitomo Dainippon Ekes Out Quarterly Growth as North America Sales Offset Japan Dip
To read the full story
Related Article
- Sumitomo Dainippon’s April-December Sales Up 2.9% as Diabetes Meds Counter Off-Patent Dip
January 31, 2020
- To Weather Latuda Cliff, Sumitomo Dainippon Looks to Cash In on Roivant Alliance to Push Priority R&D
October 29, 2019
- Sumitomo Dainippon Lifts Q2 Earnings Guidance on Solid Sales in Japan, US, China
October 23, 2019
- Sumitomo Dainippon’s Sales Down 1.6% on Price Cuts, Generic Erosions
May 13, 2019
BUSINESS
- Takeda Inks Collab with Japan Cancer Research Foundation
April 23, 2024
- Takeda, Astellas, SMBC Join Forces to Fill Vally of Death in Japan
April 23, 2024
- Astellas Challenges Negative District Court Decision in Myrbetriq Patent Row
April 23, 2024
- Healthcare Stakeholders Already Fret Smaller Coverage for LLPs
April 23, 2024
- Roche Diagnostics Files 2 Alzheimer’s Test Assays for β-Amyloid, Tau
April 22, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…